Praxis Precision (PRAX) Medicines announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All securities in the offering will be offered by Praxis. Piper Sandler, TD Cowen, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering. LifeSci Capital, Baird and Oppenheimer & Co. are acting as lead managers for the offering. H.C. Wainwright & Co. and Needham & Company are acting as co-managers for the offering.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $460 from $315 at Needham
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/31/2025, According to Top Analysts
- Praxis Precision falls -5.7%
- Compelling Risk‑Reward in Praxis Precision Medicines: Breakthrough Ulixacaltamide, Platform Upside, and $340 Target Price Support Buy Rating
- Praxis Precision rises 14.1%